Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
复制标题
DOI：
10.1016/j.canlet.2019.01.032
复制
发表时间：
2019-01-01
期刊：
影响因子：
9.7
通讯作者：
Huang, Leaf
中科院分区：
文献类型：
--
作者：
Liu, Mengrui;Song, Wantong;Huang, Leaf
实体瘤尤其是促纤维增生性肿瘤是复杂的器官样结构。肿瘤相关成纤维细胞 (TAF) 是一种基质细胞，支持癌症的发生、进展和转移。 TAF 还有助于免疫抑制肿瘤微环境 (TME) 并阻碍 T 淋巴细胞杀死肿瘤。这里讨论了 TAF 在 TME 中的作用。具体而言，TAF 形成 T 淋巴细胞渗透的屏障。 TAF 还充当 T 淋巴细胞的负调节因子。这些发现表明，靶向 TAF 是改善癌症免疫治疗的一种有前途的策略。我们之前的研究表明，治疗性纳米粒子能够分布到 TAF 中，并耗尽或灭活 TAF。这种方法是在开发针对癌症的特异性和有效免疫疗法的背景下讨论的。
Solid tumors especially desmoplastic tumors are complex organ-like structures. Tumor-associated fibroblasts (TAFs), one type of the stromal cells, support the initiation, progression, and metastasis of carcinomas. TAFs also contribute to immunosuppressive tumor microenvironment (TME) and hinder T lymphocytes in killing tumors. Here, the role of TAFs in TME is discussed. In specific, TAFs form barriers for the penetration of T lymphocytes. TAFs also act as negative regulators for T lymphocytes. These findings suggest that targeting TAFs is a promising strategy for improving cancer immunotherapy. Our previous studies have indicated the ability of therapeutic nanoparticles to distribute into, and deplete or inactivate TAFs. This approach is discussed in the context of developing specific and effective immunotherapies for cancer.